Strengths

ROIC of 13.1% indicates Bausch Health still earns acceptable returns on capital, but peers with cleaner balance sheets typically convert capital into value more efficiently.

The company’s current ratio of 1.44 and quick ratio of 1.08 suggest near-term liquidity is serviceable, which supports operating continuity better than more distressed peers.

A large cash conversion cycle of 196.5 days reflects working-capital drag, yet it also indicates room for operational normalization if collections and inventory improve versus peers.

Bausch Health’s diversified healthcare exposure can cushion single-product volatility, although peers with stronger branded franchises usually enjoy more stable demand and pricing power.

Weaknesses

Net debt to EBITDA of 9.3x signals a highly leveraged capital structure, leaving Bausch Health structurally weaker than most peers on financial flexibility and resilience.

The negative debt-to-equity ratio reflects persistent equity impairment, which constrains strategic optionality and compares poorly with peers that retain positive book equity.

A 196.5-day cash conversion cycle ties up cash for extended periods, reducing free-cash-flow efficiency versus peers with faster inventory and receivables turnover.

Limited disclosed margin data alongside heavy leverage suggests earnings quality remains difficult to assess, while stronger peers typically provide clearer and more durable profitability visibility.

Opportunities

Reducing leverage through asset sales or debt paydown could materially improve Bausch Health’s positioning, because peers with lower leverage can reinvest more aggressively.

Working-capital optimization offers a direct path to shorten the 196.5-day cash conversion cycle, which would release cash faster than many slower-moving healthcare peers.

If management sustains ROIC above its cost of capital, the company can gradually rebuild investor confidence, especially versus peers with weaker capital discipline.

Portfolio simplification could sharpen focus on higher-return assets, potentially improving margin quality relative to more complex peers with broader but less efficient product mixes.

Threats

High leverage leaves Bausch Health more exposed than peers to refinancing risk and higher interest costs, which can suppress investment capacity over a 2–5 year horizon.

A prolonged cash conversion cycle increases dependence on external financing, making the company more vulnerable than peers if credit conditions tighten or collections slow.

Competitive pressure from larger, better-capitalized healthcare peers can limit pricing power and market share gains, especially where product differentiation is modest.

Any operational setback would have an outsized effect on equity value because the balance sheet is already stretched, unlike peers with stronger capital buffers.

Overall Score

Bausch Health’s operating returns are acceptable, but its highly leveraged balance sheet and weak cash efficiency leave it structurally behind stronger healthcare peers.